EP0959886A4 - TRIARYL SUBSTITUTED IMIDAZOLES AS GLUCAGON ANTAGONISTS - Google Patents

TRIARYL SUBSTITUTED IMIDAZOLES AS GLUCAGON ANTAGONISTS

Info

Publication number
EP0959886A4
EP0959886A4 EP97948343A EP97948343A EP0959886A4 EP 0959886 A4 EP0959886 A4 EP 0959886A4 EP 97948343 A EP97948343 A EP 97948343A EP 97948343 A EP97948343 A EP 97948343A EP 0959886 A4 EP0959886 A4 EP 0959886A4
Authority
EP
European Patent Office
Prior art keywords
substituted imidazoles
glucagon antagonists
triaryl substituted
triaryl
glucagon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97948343A
Other languages
German (de)
French (fr)
Other versions
EP0959886A1 (en
Inventor
Linda L Chang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9700540.9A external-priority patent/GB9700540D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP0959886A1 publication Critical patent/EP0959886A1/en
Publication of EP0959886A4 publication Critical patent/EP0959886A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP97948343A 1996-11-20 1997-11-17 TRIARYL SUBSTITUTED IMIDAZOLES AS GLUCAGON ANTAGONISTS Withdrawn EP0959886A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US3146696P 1996-11-20 1996-11-20
GBGB9700540.9A GB9700540D0 (en) 1997-01-13 1997-01-13 Triaryl substituted imidazoles as glucagon antagonists
GB9700540 1997-01-13
PCT/US1997/021020 WO1998022109A1 (en) 1996-11-20 1997-11-17 Triaryl substituted imidazoles as glucagon antagonists
US31466P 2008-02-26

Publications (2)

Publication Number Publication Date
EP0959886A1 EP0959886A1 (en) 1999-12-01
EP0959886A4 true EP0959886A4 (en) 2001-05-02

Family

ID=26310783

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97948343A Withdrawn EP0959886A4 (en) 1996-11-20 1997-11-17 TRIARYL SUBSTITUTED IMIDAZOLES AS GLUCAGON ANTAGONISTS

Country Status (5)

Country Link
EP (1) EP0959886A4 (en)
JP (1) JP2000514088A (en)
AU (1) AU730295B2 (en)
CA (1) CA2271893A1 (en)
WO (1) WO1998022109A1 (en)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916891A (en) 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
AP9700912A0 (en) 1996-01-11 1997-01-31 Smithkline Beecham Corp Novel cycloalkyl substituted imidazoles
US6046208A (en) * 1996-01-11 2000-04-04 Smithkline Beecham Corporation Substituted imidazole compounds
PL187516B1 (en) * 1996-01-11 2004-07-30 Smithkline Beecham Corp Novel substituted derivatives of imidazole
EP0889888A4 (en) * 1996-03-25 2003-01-08 Smithkline Beecham Corp Novel treatment for cns injuries
WO1998007425A1 (en) 1996-08-21 1998-02-26 Smithkline Beecham Corporation Imidazole compounds, compositions and use
US5929076A (en) * 1997-01-10 1999-07-27 Smithkline Beecham Corporation Cycloalkyl substituted imidazoles
AU7966198A (en) 1997-06-13 1998-12-30 Smithkline Beecham Corporation Novel pyrazole and pyrazoline substituted compounds
EP0994870A4 (en) 1997-06-19 2002-10-23 Smithkline Beecham Novel aryloxy substituted pyrimidine imidazole compounds
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
US6489325B1 (en) 1998-07-01 2002-12-03 Smithkline Beecham Corporation Substituted imidazole compounds
US6251914B1 (en) 1997-07-02 2001-06-26 Smithkline Beecham Corporation Cycloalkyl substituted imidazoles
US6562832B1 (en) 1997-07-02 2003-05-13 Smithkline Beecham Corporation Substituted imidazole compounds
TW517055B (en) 1997-07-02 2003-01-11 Smithkline Beecham Corp Novel substituted imidazole compounds
CA2306077A1 (en) 1997-10-08 1999-04-15 Smithkline Beecham Corporation Novel cycloalkenyl substituted compounds
AU1924699A (en) 1997-12-19 1999-07-12 Smithkline Beecham Corporation Compounds of heteroaryl substituted imidazole, their pharmaceutical compositionsand uses
JP2002516322A (en) 1998-05-22 2002-06-04 スミスクライン・ビーチャム・コーポレイション New 2-alkyl-substituted imidazole compounds
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
DE69914357T2 (en) 1998-11-04 2004-11-11 Smithkline Beecham Corp. PYRIDIN-4-YL OR PYRIMIDIN-4-YL SUBSTITUTED PYRAZINE
DE60001229T2 (en) 1999-04-09 2003-10-30 Smithkline Beecham Corp., Philadelphia triarylimidazoles
US6503949B1 (en) 1999-05-17 2003-01-07 Noro Nordisk A/S Glucagon antagonists/inverse agonists
US6759410B1 (en) 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
EP1233950B1 (en) 1999-11-23 2005-10-05 Smithkline Beecham Corporation 3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/P39 kINASE INHIBITORS
JP2003514900A (en) 1999-11-23 2003-04-22 スミスクライン・ビーチャム・コーポレイション 3,4-Dihydro- (1H) -quinazolin-2-one compounds as CSBP / p38 kinase inhibitors
EP1743655B1 (en) 2000-01-21 2014-06-25 Novartis AG Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
US6562807B2 (en) 2000-06-23 2003-05-13 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6821960B2 (en) 2000-11-17 2004-11-23 Noyo Nordisk Pharmaceuticals, Inc. Glucagon antagonists/inverse agonists
US6706744B2 (en) 2000-11-17 2004-03-16 Novo Nordisk A/S Glucagon antagonists/inverse agonists
WO2002040445A1 (en) 2000-11-17 2002-05-23 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6881746B2 (en) 2001-12-03 2005-04-19 Novo Nordick A/S Glucagon antagonists/inverse agonists
US6762318B2 (en) 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
ES2278170T3 (en) 2002-07-09 2007-08-01 BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG PHARMACEUTICAL COMPOSITIONS OF ANTICOLINERGIC AND INHIBITORS OF QUINASE P38 IN THE TREATMENT OF RESPIRATORY DISEASES.
WO2004063147A1 (en) * 2003-01-10 2004-07-29 Novo Nordisk A/S Salts and solvates of glucagon antagonists
AU2004210127B2 (en) 2003-01-27 2009-10-01 Merck Sharp & Dohme Corp. Substituted pyrazoles, compositions containing such compounds and methods of use
CA2547785A1 (en) 2003-12-19 2005-07-21 Merck & Co., Inc. Cyclic guanidines, compositions containing such compounds and methods of use
NZ551405A (en) 2004-06-04 2009-06-26 Merck & Co Inc Pyrazole derivatives, compositions containing such compounds and methods of use
CN1980665A (en) 2004-07-07 2007-06-13 默克公司 Pyrazole amide derivatives, compositions containing such compounds and methods of use
WO2006014618A2 (en) 2004-07-22 2006-02-09 Merck & Co., Inc. Substituted pyrazoles, compositions containing such compounds and methods of use
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
PE20060777A1 (en) 2004-12-24 2006-10-06 Boehringer Ingelheim Int INDOLINONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
US8318760B2 (en) 2005-03-21 2012-11-27 Merck Sharp & Dohme Corp. Substituted aryl and heteroaryl derivatives, compositions containing such compounds and methods of use
JP2008534593A (en) 2005-03-30 2008-08-28 メルク エンド カムパニー インコーポレーテッド Glucagon receptor antagonist compounds, compositions containing such compounds, and methods of use thereof
CN101300232A (en) 2005-07-26 2008-11-05 默克公司 Process for the synthesis of substituted pyrazoles
PT1931350E (en) 2005-09-14 2014-02-12 Takeda Pharmaceutical ADMINISTRATION OF DIPEPTIDIL PEPTIDASE INHIBITORS
TW200745031A (en) 2005-10-13 2007-12-16 Merck & Co Inc Acyl indoles, compositions containing such compounds and methods of use
US7989472B2 (en) 2006-03-23 2011-08-02 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US7935713B2 (en) 2006-05-16 2011-05-03 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
TW200821284A (en) 2006-10-03 2008-05-16 Merck & Co Inc Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
PL2531501T3 (en) 2010-02-03 2014-05-30 Takeda Pharmaceuticals Co Apoptosis signal-regulating kinase 1 inhibitors
NZ611529A (en) 2010-12-23 2015-06-26 Pfizer Glucagon receptor modulators
WO2012107850A1 (en) 2011-02-08 2012-08-16 Pfizer Inc. Glucagon receptor modulator
US8927577B2 (en) 2011-07-22 2015-01-06 Pfizer Inc. Quinolinyl glucagon receptor modulators
EP3065736B1 (en) 2013-11-04 2018-11-14 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions thereof, and methods of use

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3707475A (en) * 1970-11-16 1972-12-26 Pfizer Antiinflammatory imidazoles
US3929807A (en) * 1971-05-10 1975-12-30 Ciba Geigy Corp 2-Substituted-4(5)-(aryl)-5(4)-(2,3 or -4-pyridyl)-imidazoles
WO1993014081A1 (en) * 1992-01-13 1993-07-22 Smithkline Beecham Corporation Imidazole derivatives and their use as cytokine inhibitors
WO1995003297A1 (en) * 1993-07-21 1995-02-02 Smithkline Beecham Corporation Imidazoles for treating cytokine mediated disease
WO1996018626A1 (en) * 1994-12-13 1996-06-20 F. Hoffmann-La Roche Ag Imidazole derivatives as protein kinase inhibitors in particular egf-r tyrosine kinase
WO1996021654A1 (en) * 1995-01-12 1996-07-18 Smithkline Beecham Corporation Novel compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620999A (en) * 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3707475A (en) * 1970-11-16 1972-12-26 Pfizer Antiinflammatory imidazoles
US3929807A (en) * 1971-05-10 1975-12-30 Ciba Geigy Corp 2-Substituted-4(5)-(aryl)-5(4)-(2,3 or -4-pyridyl)-imidazoles
WO1993014081A1 (en) * 1992-01-13 1993-07-22 Smithkline Beecham Corporation Imidazole derivatives and their use as cytokine inhibitors
WO1995003297A1 (en) * 1993-07-21 1995-02-02 Smithkline Beecham Corporation Imidazoles for treating cytokine mediated disease
WO1996018626A1 (en) * 1994-12-13 1996-06-20 F. Hoffmann-La Roche Ag Imidazole derivatives as protein kinase inhibitors in particular egf-r tyrosine kinase
WO1996021654A1 (en) * 1995-01-12 1996-07-18 Smithkline Beecham Corporation Novel compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GALLAGHER T F ET AL: "2,4,5- Triarylimidazole inhibitors of IL-1 biosynthesis", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,GB,OXFORD, vol. 5, no. 11, 8 June 1995 (1995-06-08), pages 1171 - 1176, XP004135499, ISSN: 0960-894X *
See also references of WO9822109A1 *

Also Published As

Publication number Publication date
CA2271893A1 (en) 1998-05-28
WO1998022109A1 (en) 1998-05-28
AU5442898A (en) 1998-06-10
AU730295B2 (en) 2001-03-01
EP0959886A1 (en) 1999-12-01
JP2000514088A (en) 2000-10-24

Similar Documents

Publication Publication Date Title
EP0959886A4 (en) TRIARYL SUBSTITUTED IMIDAZOLES AS GLUCAGON ANTAGONISTS
EP0934305A4 (en) INTEGRINE ANTAGONISTS
FI942432L (en) Arrangement for connecting the elevator machine to the building
PT805813E (en) TRASTERIC VASOPRESSIN ANTAGONISTS
EP0758238A4 (en) SPIRO-SUBSTITUTED AZACYCLES USED AS NEUROKININ-3 ANTAGONISTS
FI970523A7 (en) (Azetidin-1-ylalkyl)lactams as tachykinin antagonists
FI955258L (en) Substituted pyrrolidin-3-yl-alkyl-piperidines useful as tachykinin antagonists
FI960840A7 (en) Indole derivatives as thromboxane A2 antagonists
PT738150E (en) FIBRINOGENIC BICYCLE ANTAGONISTS
FI933810L (en) Receptor antagonists av exiterbara aminosyror
FI960516L (en) Substituted biphenylsulfonamide dientothelin antagonists
EP0866705A4 (en) FIBRINOGEN RECEPTOR ANTAGONISTS
DE59606460D1 (en) Boring bar
PT831697E (en) MICROBICIDE COMPOSITIONS
DE69626556D1 (en) Biocidal compositions
FI951189L (en) N-cyano-N'-pyridylguanidines acting as serotonin antagonists
MX9100717A (en) BRADIQUININE ANTAGONISTS
FI953916L (en) Fibrinogen receptor antagonists
FI945807A7 (en) 2,5-dioxo-2,5-dihydro-1H-benz/b/azepines as NMDA receptor antagonists
DE69622731D1 (en) TETRAHYDROCHINOLINE AS NMDA ANTAGONISTS
EP0708765A4 (en) PIPERAZINYLCAMPHER DERIVATIVES SUBSTITUTED AS OXYTOCIN ANTAGONISTS
DE59206461D1 (en) Sizing scaffolding group
EP0966479A4 (en) POLYPROLYL ACTING AS A CYCLOPHILINE INHIBITOR
FI943513L (en) 3-Phenylureidoazepin-2-ones and -benzazepin-2-ones useful as cholecystokinin antagonists
NO930262L (en) Bombesin ANTAGONISTS

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990621

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20010321

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 31/44 A, 7C 07D 401/04 B

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040602